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Metal complexes as a promising source for new antibiotics
Generally, metal complexes are associated with inherent 
toxicity and not deemed suitable for drug development. This 
work showcases an analysis of the antimicrobial properties 
of 906 metal-containing compounds in a database assembled 
by the Community for Open Antimicrobial Drug Discovery 
(CO-ADD). It is shown, that compared to the almost 
300’000 organic compounds, metal complexes have a 
signifi cantly higher hit-rate against critical bacterial and 
fungal pathogens. Additionally, metal-compounds display 
the same toxicity and haemolysis rates as their organic 
counterparts against human cells. The variety of structures 
found in this analysis highlights the many possibilities that 
metal complexes can bring to drug discovery.
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There is a dire need for new antimicrobial compounds to combat the growing threat of widespread
antibiotic resistance. With a currently very scarce drug pipeline, consisting mostly of derivatives of known
antibiotics, new classes of antibiotics are urgently required. Metal complexes are currently in clinical
development for the treatment of cancer, malaria and neurodegenerative diseases. However, only little
attention has been paid to their application as potential antimicrobial compounds. We report the
evaluation of 906 metal-containing compounds that have been screened by the Community for Open
Antimicrobial Drug Discovery (CO-ADD) for antimicrobial activity. Metal-bearing compounds display
a significantly higher hit-rate (9.9%) when compared to the purely organic molecules (0.87%) in the
CO-ADD database. Out of 906 compounds, 88 show activity against at least one of the tested strains,
including fungi, while not displaying any cytotoxicity against mammalian cell lines or haemolytic
properties. Herein, we highlight the structures of the 30 compounds with activity against Gram-positive
and/or Gram-negative bacteria containing Mn, Co, Zn, Ru, Ag, Eu, Ir and Pt, with activities down to the
nanomolar range against methicillin resistant S. aureus (MRSA). 23 of these complexes have not been
reported for their antimicrobial properties before. This work reveals the vast diversity that metal-
containing compounds can bring to antimicrobial research. It is important to raise awareness of these
types of compounds for the design of truly novel antibiotics with potential for combatting antimicrobial
resistance.Introduction
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View Article Onlinetreatments.80 Furthermore, almost 75% of the antimicrobials
under clinical development are simply derivatives of already
known and used antibiotics, meaning that they will likely be
prone to existing resistance mechanisms. To make things
worse, only one of the remaining 11 entirely new compounds is
effective against the notoriously more resilient Gram-negative
strains.1 Commercial development of new antibiotics is
unlikely to rell the antibiotic pipeline in the near future, with
the number of pharmaceutical companies actively researching
new antibiotics still shrinking every year due to the unfavorable
return on investment in the eld.2,3
A recurrent trend in the antibiotic chemical landscape is that
antibacterial compounds are rarely “drug-like”, i.e. they do not
conform to the physicochemical and reactive functionality
guidelines developed to direct the discovery of new orally
available therapies. This means that many potential new anti-
biotics have already been excluded from synthetic libraries that
are designed with these common drug-design axioms in mind,
particularly those developed within the pharmaceutical
industry (e.g. following Lipinski's Rule of Five4). To circumvent
this inherent medicinal chemistry bias, our research group has
embarked on a quest to tap into the millions of diverse
compounds prepared in academic chemistry laboratories across
the world, new molecules with a range of shapes and sizes that
have been synthesized for methodology development or for
other biological applications, and which are oen simply sitting
on a shelf somewhere, unused. In the last four years the
Community for Open Antimicrobial Drug Discovery (CO-ADD)
has offered scientists worldwide access to a simple and free
screening service where any submitted compound could be
evaluated against key bacterial and fungal pathogens.5,6 By
leaving all IP rights in the hands of the originators and
employing a widespread campaign, marketing our service, we
have received and screened over 295 000 compounds from 280
academic groups from 46 countries. A substantial proportion of
compounds submitted to CO-ADD fall within the accepted
denitions of “drug-likeness”, demonstrating the extent to
which these rules have permeated even academic research
efforts. Fortunately, we have also received a considerable
number of compounds that lie outside such conventions, with,
for example, low lipophilicity (log D < 2) and larger molecular
weight (MW > 500). In addition, a considerable number of metal-
containing compounds were found amongst the submitted
compounds, which are the focus of this report.
A common denominator of lead structures in the pharma-
ceutical industry and most compounds developed by medicinal
chemists across the globe is that they are almost exclusively
purely organic compounds. At rst sight, this might seem
intuitive as metals and their complexes are mostly known for
their application as materials or catalysts and are oen associ-
ated with toxicity. However, metal-based coordination
complexes have played a crucial role in medicine throughout
history, including the use of arsenic for the rst effective
treatment of syphilis (Salvarsan), mercury in the topical anti-
septic mercurochrome or the vaccine preservative thiomersal,
and gold in the treatment of rheumatoid arthritis (Auranon).7,8
Metal complexes became a cornerstone of medicinal chemistry2628 | Chem. Sci., 2020, 11, 2627–2639with the approval of the chemotherapeutic platinum-based
drug Cisplatin (1978), which is still used in a majority of all
cancer treatments today.9 In the last two decades, several more
titanium-, iron-, ruthenium-, gallium-, palladium-, silver-, gold-,
bismuth-, and copper-based metal complexes have reached
human clinical trials as treatments for cancer, malaria and
neurodegenerative diseases.10–13,81,82 A palladium-based photo-
dynamic therapy agent was approved in 2019 for the treatment
of prostate cancer by the European Medicines Agency (EMA).83
Many more elements are actively being investigated for a range
of medical applications.14,15
However, only a few studies have focused on antibacterial
applications. Bismuth- and silver-based antimicrobials are the
only elements used in some clinical interventions. Bismuth is
co-administered in combination with other antibiotics for the
treatment of Helicobacter pylori infections.16–18 Xeroform,
namely tribromophenatebismuth(III), is used as an antimicro-
bial in wound dressing applications.19 A bismuth-thiol
compound (pravibismane) just completed a phase 1b clinical
trial for the treatment of infected diabetic foot ulcers.20 Silver is
also used in a variety of forms for the treatment of wounds and
management of infections.16 Silver sulphadiazine is applied
either as a cream or aqueous solution for the topical treatment
of some burn wounds. However, the effectiveness of these silver
compounds has been questioned in the last years. In recent
trials, topically applied silver-based compounds performed only
equal or worse than non-silver based treatments.21–23
Despite these few, rather unspecic metal-based treatments,
the inorganic chemistry space is still largely ignored for anti-
microbial applications. This is unfortunate because the
tremendous variety of three-dimensional structural scaffolds
available through metal coordination chemistry is an ideal
starting point for the exploration of novel chemical space for
new antibiotic compounds and provides a ready “escape from
atland”.24,25 This argument has recently been validated
through seminal work by Morrison et al. The authors show that
while themajority of organic molecules have simple one- or two-
dimensional shapes, metal complexes can easily access hitherto
underexplored three-dimensional chemical space. A small
library of 71 ‘metallofragments’ was assembled and shown to
cover a signicantly larger portion of the available geometrical
space with 77% of the compounds possessing a three-
dimensional shape (compared to 25% of a 18 435 molecule
library of organic fragments).26
In addition, metal complexes have access to uniquemodes of
action: ligand exchange or release, ROS generation, redox acti-
vation and catalytic generation of toxic species or depletion of
essential substrates. Such mechanisms are difficult if not
impossible to replicate with purely organic compounds.27,28
We scanned the CO-ADD database for metal-containing
compounds and found close to 1000 structures that had been
submitted and evaluated over the last four years. Herein we
report the analysis of the antibacterial and antifungal activity of
what is to date the largest dataset of metal complexes tested for
antimicrobial activity. We show that metal-based compounds
display a signicantly higher hit-rate against critical ESKAPE
pathogens and fungi when compared to the solely organicThis journal is © The Royal Society of Chemistry 2020
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View Article Onlinecompounds within the CO-ADD collection. While the data are
still too sparse for any specic structure–activity relationship
evaluation, we believe this study can serve as an important
roadmap, highlighting which metals and ligands have proven
promising and are therefore worthy of further study and,
conversely, which ones have not yet been explored. We hope
that through this work we can encourage more researchers
worldwide to submit their metal compounds for screening in
order to expand this open library and to gather more detailed
data.Results and discussion
Scope
We have dened the scope of the termmetal complex to include
all d-block elements and the lanthanides, as well as the post-
transition metals gallium, indium, tin, thallium, lead and
bismuth, but have excluded the actinides and the rare/
radioactive d-elements with atomic number >100, as well as
the radioactive elements technetium and promethium, leaving
49 elements. A total of 906 individual compounds containing 29
of these 49 possible metal elements (Fig. 1) have been evaluated
by CO-ADD (as of July 2019). These compounds have been
submitted by 47 research groups from 17 different countries
across the world. Fig. 2 shows a detailed elemental distribution
of the compounds submitted (black bars). Amongst the
submissions, 63 compounds contained two metal centers.
The more abundant rst-row d-block elements represent
almost 50% of all compounds. However, it is the second-row
transition metal ruthenium that has the highest number of
submissions. This is likely a consequence of the trend of
ruthenium-based compounds for anticancer applications in the
last years, fueled by the advancement into clinical trials ofFig. 1 Periodic table highlighting the elements classified as metals for the
contained in compounds that have been submitted to CO-ADD to
(www.supersciencegrl.co.uk).
This journal is © The Royal Society of Chemistry 2020NAMIA-A, KP1019 and very recently TLD1433, which has led to
many inorganic medicinal chemistry groups investigating these
types of compounds.12
Compounds are submitted to CO-ADD as dry powders,
conrmed to be at >95% purity by the collaborators, and then
tested as received. Characterization of the complexes is done by
the submitting research group. No quality control check of
purity is performed by CO-ADD due to the volume of
compounds received; false positives are therefore possible and
promising compounds should be checked thoroughly before
further development. The antimicrobial assays are done in
duplicates and the data added to the database only if consistent
results are obtained between runs. Compounds that are
submitted to CO-ADD rst undergo a primary screening where
they are tested at a xed concentration (usually 32 mg mL1 or
20 mM, depending on the provided stock solution) against key
bacterial (Escherichia coli, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, methicillin resistant
Staphylococcus aureus (MRSA)) and fungal (Cryptococcus neofor-
mans (yeast) and Candida albicans) pathogens. If the compound
shows any signicant inhibition at this concentration, a follow-
up hit conrmation is triggered, where the activity is measured
by means of a dose–response assay against the same strains. We
ltered the 906 metal complex entries to identify compounds
with at least a minimal amount of activity, dened as
a minimum inhibitory concentration (MIC) value of equal to or
lower than 16 mg mL1 (or 10 mM) against at least one organism.
A total of 246 compounds qualied as active under these
criteria, representing a hit-rate of 27% over the entire set of
metal compounds. In comparison, the overall hit-rate for CO-
ADD is 1.6% (4620 actives out of 287 385 screened, excluding
the metal compounds). While this substantially higher hit-rate
is extraordinary, it is conceivable that many metal complexespurpose of this study (white) and the subset of these elements that are
date (orange). Figure adapted with permission from Nessa Carson
Chem. Sci., 2020, 11, 2627–2639 | 2629
Fig. 2 (A) Elemental distribution of all 906 metal-containing compounds submitted to CO-ADD (black); 246/906 submitted metal-containing
compounds with at least one MIC lower or equal to 16 mg mL1 or 10 mM (red) against the tested organisms; 88/246 active metal-containing
compounds with no cytotoxicity or hemolytic activity at the highest concentration tested (blue). (B) Metal frequency amongst the 906 metal-
containing compounds submitted to CO-ADD. (C) Metal frequency amongst the 246 metal complexes that possess some activity against the
tested organisms. (D). Metal frequency amongst the 88 compounds that are active as well as ‘non-toxic’ (see text for definition). (E) Percentage of
submittedmetal-containing compounds with antimicrobial activity, compared to the overall hit rate for organic compounds within the CO-ADD
collection.
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View Article Onlinesimply possess general toxicity that is not specic to bacteria
but also affects human cells. Given that a signicant subset of
these compounds was made with anticancer applications in
mind, where cytotoxic properties are desirable, this is
a concern. To address this issue, toxicity was assessed by
measuring mammalian cell viability (HEK293 human embry-
onic kidney cells) and haemolytic activity against human red
blood cells. Non-toxic compounds were dened as compounds2630 | Chem. Sci., 2020, 11, 2627–2639with HEK293 CC50 > 32 mgmL
1 or >20 mMand haemolytic HC10
> 32 mg mL1 or >20 mM (HC10 is the concentration causing 10%
haemolysis). Removing all hits that displayed toxicity and/or
haemolysis le 88 metal-containing compounds, a hit-rate of
9.9% for non-cytotoxic hits, still substantially enhanced (>10-
fold higher) compared to 0.87% for the general CO-ADD library.
Of note, the percentage of toxic and/or haemolytic compounds
was found to be nearly identical when comparing the metalThis journal is © The Royal Society of Chemistry 2020
Fig. 3 (A) Percentage of submitted compounds that were found to be
active, classified by element. (B) Percentage of submitted compounds
that were found to be active and ‘non-toxic’, classified by compounds
per element that are also non-toxic. (C) Overall success-rate of
compounds, classified by element.
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View Article Onlinecompounds with the rest of the CO-ADD library (64.2% vs.
64.5%). Overall, this analysis indicates that a higher degree of
general toxicity can be ruled out as the cause for the extraor-
dinarily high hit-rate for active metal-bearing compounds
compared to organic molecules.
Amongst the metal complexes, ruthenium was the most
frequent element found in active ‘non-toxic’ compounds, fol-
lowed by silver, palladium and iridium. Copper, iron, cobalt and
zinc stand out as ‘underperformers’, with fewer than 20% of the
submitted complexes showing any activity at all (Fig. 3). InFig. 4 Activity distribution of metal complexes between the different cla
ATCC 43300) and E. coli (ATCC 25922) shown as box plot (first and thir
This journal is © The Royal Society of Chemistry 2020general, rst-row transition metal ions undergo ligand substi-
tution more rapidly than the second and third row elements.
This could indicate that these compounds react more quickly
with components in the medium and are not able to enter the
bacterial cells. Another possibility is that the bacteria are able to
efflux essential metals more easily as their biochemistry is
familiar to them.
When these compounds are further broken down according
to their activity prole, 58 of them were exclusively antifungal,
while the other 30 were active against at least one bacterial
strain (Fig. 4). As antibacterial agents, most entries showed the
best activity against Gram-positive MRSA, as is generally true for
the entire set of CO-ADD screened compounds. Finally, only 14
compounds showed any activity (MIC# 32 mg mL1) against the
Gram-negative strains tested, i.e. 1.5% of all submitted
compounds. While this number is rather low, it is still signi-
cantly larger than the overall CO-ADD value of 0.16%, and is
consistent with the inherent difficulty of nding compounds
active against Gram-negative bacteria (e.g. a GSK screen of
500 000 k synthetic compounds against S. aureus and E. coli
found thousands of Gram-positive actives with 300 considered
for further evaluation, but no ‘non-nuisance’ Gram-negative
hits29).
Gallium, palladium, silver, cadmium, iridium and platinum
show the highest overall success rate. However, the overall
numbers of submitted cadmium and gallium complexes were
very low (5 and 6 respectively), limiting the ability to make
general statements. Historically, both silver and gallium have
been known to possess antimicrobial activity, a trend that is
somewhat conrmed here.30–34 However, a signicant portion of
the silver complexes evaluated in this study also displayed
cytotoxicity. While Pd, Ir and Pt complexes showed promising
activities, these elements are relatively rare and expensive,
possibly limiting their use as clinical antibiotics if large doses
are required. Amongst the more common elements, iron stands
out as one of the least effective metals: of 108 compounds
tested, only 20 showed any kind of activity and all of those
turned out to be cytotoxic and/or haemolytic, ruling out this
subsample of iron complexes as possible antibiotics.sses of bacteria (left) and as distribution of the MIC for S. aureus (MRSA,
d quartile) with median (line), mean (cross) and outliers (dots).
Chem. Sci., 2020, 11, 2627–2639 | 2631
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View Article OnlineFig. 5 shows the structures of the 30 compounds with activity
against at least one bacterial strain and no toxicity or haemo-
lytic properties at the highest tested concentration. In general,Fig. 5 Structures of metal complexes that showed activity against strains
concentration.
2632 | Chem. Sci., 2020, 11, 2627–2639multiple examples of a submitted compound series are present,
but in each case there are usually multiple similar compounds
that are either not active or cytotoxic and/or haemolytic toand were not toxic and/or haemolytic to mammalian cells at the same
This journal is © The Royal Society of Chemistry 2020
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Fe
br
ua
ry
 2
02
0.
 D
ow
nl
oa
de
d 
on
 4
/2
0/
20
20
 4
:2
1:
15
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinehuman cells, providing some evidence of potential for further
optimization and structure–activity relationship investigations.
The structures of the exclusively antifungal compounds are not
shown here and will be discussed elsewhere. The synthesis and
characterization of all compounds shown here except silver
complexes 2–9 has been previously reported in peer-reviewed
publications (Table S3†). Since the exact structure of the silver
carboxylates is not known, they are shown as carboxylate-
coordinated species. In reality, these compounds are probably
present as carboxylate-bridged oligomers.
An issue that is oen raised for medicinal applications
regarding metal complexes, but also organic molecules, is their
stability in biological systems. While inertness is certainly not
a requirement for good activity, as is showcased by cisplatin, it
is paramount to understand the behavior of these compounds
in biological systems. Stability studies in both common solvents
as well as biological media and human blood should therefore
be conducted for any metal-containing compound if it is to be
considered for further development. In the case of the struc-
tures showcased in this work, a few general remarks can be
made about their putative stability. The silver complexes 1–9 are
likely to dissociate at some point when exposed to biological
media. The different activity proles of the compounds (vide
infra) suggest that the nature of the ligand can dictate the time
and place where the dissociation will occur, modulating the
biological effect of the released silver ions. The other
compounds are unlikely to dissociate to the point of releasing
the metal ion, but some degree of ligand substitution is prob-
able for most complexes highlighted here. The platinum
compounds 16–18 and 19 are likely to undergo ligand exchange
reactions when exposed to solvents and media. Reminiscent of
cisplatin these reactions might actually lead to the formation of
the active species in these cases. The axial ligands of 21 and 22
are known to be labile and are likely to undergo substitution
reactions in vitro as well.35 Similarly, the chlorido and 1,3,5-
triaza-7-phosphaadamantane (PTA) ligands in complexes 10–15
are prone to substitution.36 Ligand exchanges are conceivable
for 23–25 but the biological behavior of these types of
compounds has not been studied extensively yet. Ruthenium
complex 27 has been shown to be stable in water for at least 24 h
while the chloride ligand of 30 is readily replaced by water.
However, the monodentate ligands have been reported to be
released by light irradiation (520 nm, 1 h, 53 J cm2) in the case
of 27 and by inference this is probable for 28 and 29 as well,
showcasing an example of interesting alternative modes of
action that are possible with metal complexes.37 The fact that
many of the more active compounds are likely to undergo
ligand-exchange reactions when exposed to solvents and/or
media suggests that the shown structures are potentially “pro-
drug-like”molecules and highlights that a traditional medicinal
chemistry mindset cannot be applied indiscriminately to metal
complexes.
Table 1 shows theMIC values of these 30 compounds against
the CO-ADD panel of microorganisms as determined by broth
microdilution assay. The xanthine derived N-heterocyclic car-
bene (NHC) complex of silver(I) (1) turned out to be the
compound with best broad-spectrum activity, showingThis journal is © The Royal Society of Chemistry 2020moderate MICs against all tested strains and no cytotoxicity
and/or haemolysis.38 Compounds 2–9 contain Ag(I) with various
carboxylate ligands. Interestingly, they show distinct activity
proles and several similar compounds did not show any
activity, suggesting that different silver–ligand combinations
lead to signicantly different biological behavior, and that the
silver content alone is not responsible for the observed activity.
The antibacterial properties of some carboxylate silver(I)
complexes have been summarized in a recent review article.39
NHC–silver carbenes are amongst the more intensely investi-
gated metal complexes for antibacterial activity, andmany more
silver compounds have been reported, with the results
summarized in several review articles.40–42 Furthermore, new
advances have revealed detailed information on possible modes
of action for silver-based antimicrobial compounds.43,44 Silver
itself is known to be an antimicrobial agent, with varying
activity depending on form (salts vs. nanoparticles vs. colloidal
forms), so analysis of activity of silver complexes is complicated
by this inherent activity.45,46 Altogether, our data support the
published literature and highlights that silver compounds are
a proven starting point for preparation of new potential anti-
biotic compounds.
Amongst the series of iridium(III) complexes 10-15, only 12
showed activity against some of the Gram-negative strains, in
addition to the overall excellent activity of this compound series
against the two fungal strains and MRSA. The group submitting
these compounds have recently reported a detailed study on
a larger series of iridium-based complexes, in which they
describe potent activity against a series of Gram-negative, Gram-
positive and fungal strains in conjunction with high complex
stability and generally low toxicity. Additionally, synergistic
activity with the antibiotic vancomycin was demonstrated,
together with the ability to disrupt bacterial biolms.36 By
comparing the active structures with similar but inactive
analogs, it becomes clear that the overall structure of the
complex is crucial for the activity of these compounds. For
example, analogous complexes with no phenyl or only one
phenyl substituent on the cyclopentadiene ligand (Ir-2 and Ir-3,
ESI†), show almost no antimicrobial activity (MRSA, MIC ¼ 32
and 16 mg mL1, respectively, with no activity against the other
organisms tested). The same is true for the biguanide ligand on
its own (Ir-1, inactive at the highest tested concentration).
Furthermore, small changes of the ligand, like the switch from
a methyl-substituted to a uoro-substituted phenyl group, or
exchange of the chloro-ligand to a bromo or iodo, all produced
compounds with elevated cytotoxicity but also broad activity
against the other tested organisms (Ir-4, Ir-5 and Ir-6, ESI†).
Taken together this example illustrates that the observed
activity does not derive solely from the metal ion or the ligand
system, but that in this case the whole is more than the sum of
its parts.
All the platinum complexes (16–20) were generally active
against MRSA and the two tested fungal strains. The platinum-
cyclooctadiene type complexes have been studied mainly as
precursors, e.g. for metal organic vapor deposition (MOCVD) or
supercritical uid reactive deposition (SFRD) for the manufac-
ture of optoelectronics or catalysts.47,48 In addition to structuresChem. Sci., 2020, 11, 2627–2639 | 2633
Table 1 MIC and cytotoxicity values for the 30 metal complexes that showed activity against at least one bacterial strain. Gve; Gram-negative
bacteria, G+ve; Gram-positive bacteria, N.d; not determined
a Ab – Acinetobacter baumannii ATCC 19606. b Ec – Escherichia coli ATCC 25922. c Kp – Klebsiella pneumoniae ATCC 700603 (K6; ESBL SHV-18). d Pa –
Pseudomonas aeruginosa ATCC 27853. e Sa – Staphylococcus aureus ATCC 43300 (MRSA). f Ca – Candida albicans ATCC 90028. g Cn – Cryptococcus
neoformans var grubii H99 ATCC 208821. h CC50 – HEK293 human embryonic kidney cells ATCC CRL-1573.
i Colistin. j Vancomycin. k Fluconazole.
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View Article Onlineto 17 and 18, seven similar structures showed selective activity
against the two fungal strains tested. Previously reported
compounds of this class showed elevated toxicity against HeLa
cells.49 Further studies to determine the active species of these
compounds are certainly required. All these platinum
compounds feature the metal in a +2 oxidation state. Recently,
investigations into the application of Pt(IV) complexes as pro-
drugs that are reduced to Pt(II) at the target site have gained a lot
of attention.9 This principle could potentially also be applied for
antibacterial purposes. Further investigations into these types
of complexes certainly seem warranted. Compound 19 is the
only platinum agent that displayed mild activity against E. coli2634 | Chem. Sci., 2020, 11, 2627–2639and K. pneumoniae. Compounds 19 and 20 were previously re-
ported for their luminescent properties.50 Two similar
complexes (Pt-1 and Pt-2, ESI†) were inactive.
The cobalt(III) complexes 21 and 22 showed some activity
against MRSA and the fungal strains. A detailed account on the
physical properties and ligand substitution reactions of these
complexes was recently published.35 These compounds also
represent the only entries for this structure class so further
studies will be needed to elucidate the full potential of these
cobalt-based derivatives.
The four ruthenium(II) complexes (27–30), showed excellent
activity againstMRSA as well as the two fungal strains. Two of themThis journal is © The Royal Society of Chemistry 2020
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View Article Onlinealso showed mild activity against the Gram-negative strain A. bau-
mannii. As mentioned earlier, compound 27 was reported previ-
ously for promising light-mediated activity against cancer cells.37
Possibly the activity of these compounds could be even better upon
light irradiation. In general, ruthenium complexes, particularly
polynuclear ones, have been reported to have favorable antimi-
crobial properties already in the 1950s by Dwyer51–53 and more
recently by the groups of Collins and Keene.54–60 Together with very
recent work on promising dinuclear ruthenium-based complexes,
these results highlight that on top of their excellent anticancer
activity, ruthenium-based compounds could also have potential
antibacterial applications.61–65
Of the remaining entries, the manganese complex 24 stands
out for its specic activity against E. coli, with the unrelated Mn
compound 25 showing activity against only MRSA. Compound 25
has been studied previously as a superoxide dismutase and cata-
lase mimic.66 The europium(III) phenanthroline complex (23) and
zinc(II) cyclam complex (26) have unusual structures and their
antibacterial activities are limited to MRSA strains. The europium
complex is part of the lanthanide uorobenzoate class of
compounds.67,68 It has good luminescent properties which make it
suitable for applications in cellular imaging, immunoassays and
organic light-emitting diodes.69–71 The zinc complex 26 is related to
a class of macrocyclic metal complexes recently shown to have
promising activity against Mycobacterium tuberculosis,72,73 and was
synthesized as part of a broader project to develop functionalized
macrocycles for biological applications.74,75 The unusual structure
of these compounds makes them interesting scaffolds for further
studies into their biological behaviour.
There appeared to be some general species selectivity among
the Gram-negative activity, with trends towards greater potency
against A. baumannii and E. coli compared to K. pneumoniae and P.
aeruginosa. However, given the limited number of active
compounds and the narrow window between the active MICs and
the highest concentrations tested, these observations are prelim-
inary. We do note that a 2014 report on polynuclear ruthenium
complexes found reduced P. aeruginosa susceptibility.76
Conclusion
We have analyzed 906 metal-containing compounds for their
antibacterial and antifungal activity and found an impressive
success rate when compared to purely organic compounds. The
syntheses of some of these compounds have previously been
reported and the antibacterial properties of 7 of the 30 shown
structures were partially described elsewhere. The 23 remaining
complexes have not been reported for their antimicrobial
activity before. Our analysis of this set of compounds highlights
the vast diversity of metals, types of ligands, and geometries
that are possible with metal compounds. This nding is in good
agreement with the recent report by Morrison et al. demon-
strating the utility of metal complexes in accessing underex-
plored chemical space for drug development.26 It is evident that
more compounds need to be tested before detailed trends can
be determined and ultimately predicted. Nevertheless, these
structures may serve as starting points for further structure–
activity explorations as they constitute interesting and muchThis journal is © The Royal Society of Chemistry 2020needed new structural classes with antimicrobial activity that
could potentially be improved upon. It is possible that for many
compounds, the lack of Gram-negative activity is due to limited
cellular entry or susceptibility to extensive efflux pump removal
from the bacteria, and additional structural modications
might be able to overcome these barriers. This work under-
scores the far-reaching diversity and potential that metal
compounds can bring to the eld of antibiotic drug discovery.
An analysis of the active but non-toxic hits provides some
preliminary insights into the more suitable elements and
structures while also pointing out where the chemical space
remains uncharted. There are obviously substantial barriers
that must be overcome that are not addressed in this study,
particularly in vivo stability and toxicity. Another question that
will have to be addressed is the mechanism of action of these
compounds, and indeed what the active compound is, e.g. what
interactions occur within the bacteria that may modify the
initial metal complex before the compound kills the cells.
Several general modes of action can be envisioned, and these
will likely vary between different classes of compounds. A metal
complex can be inert, i.e. the ligand framework stays intact and
the whole compound binds a specic bacterial target. The
compound can be partially labile, i.e. some ligands could be
exchanged in different environments and generate a species
that can bind a bacterial target or is by itself reactive/toxic. It can
also be the released ligands that are responsible for the
observed activity. Finally, the activity could be fully metal-
mediated and the ligand framework merely serves as a vehicle
to deliver the activemetal ion. Previously, Alessio and coworkers
have categorized anticancer metal complexes based on their
possible mode of action, a classication that can be applied to
metal-based antibiotics as well.28 The group of Sun has very
recently reported a series of detailed studies on the targets and
modes of action of gallium, silver and bismuth against
bacteria.43,77–79 Such metalloproteomic approaches will be very
valuable to further determine the behavior and targets of these
compounds and aid the design of improved metalloantibiotics.
The combination of an extended arsenal of possible modes
of action with a broader coverage of three-dimensional chem-
ical space make a strong case for metal complexes as potential
(antibiotic) drug candidates with some key advantages over
their organic counterparts.
Given the scarcity of new antibiotics currently in the pipe-
line, we hope to raise the awareness of the potential of metal
compounds for antimicrobial applications and inspire further
investigations into their development. In particular, we wish to
encourage additional researchers to send their metal
compounds to CO-ADD so that we can expand this open data-
base and boost investigations into metal compounds as
potential antibiotics.
Methods
Purity of compounds
All compounds were obtained as dried powders from collabo-
rators and conrmed by the collaborator to be at >95% purity.
No further purication was performed by CO-ADD. The dryChem. Sci., 2020, 11, 2627–2639 | 2635
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View Article Onlinecompounds were dissolved to a concentration of 10 mg mL1 or
10 mM in DMSO. Samples were diluted to a nal testing
concentration of 32 mg mL1 or 20 mM, depending on the
available stock solution, while keeping the nal DMSO
concentration to a maximum of 0.5%, and serially diluted 1 : 2
fold for 8 times.
Antibacterial assays
For the all the bacterial assays, each strain was cultured in
Cation-adjusted Mueller Hinton broth (CAMHB; Bacto Labora-
tories 212322) at 37 C overnight. A sample of each culture was
then diluted 40-fold in fresh CAMHB and incubated at 37 C for
1.5–3 h. The resultant mid-log phase cultures were diluted with
CAMHB (CFU mL1 measured by OD600), then added to each
well of the compound-containing plates (384-well non-binding
surface (NBS) plates; Corning CLS3640), giving a cell density
of 5  105 CFU mL1 and a total volume of 50 mL. Plates were
covered and incubated at 37 C for 18 h without shaking.
Inhibition of bacterial growth was determined measuring
absorbance at 600 nm (OD600), using media only as negative
control and bacteria without inhibitors as positive control. MIC
values were determined as the lowest concentration at which
the growth was inhibited at $80%. Colistin sulfate (Sigma
C4461) and vancomycin HCl (Sigma 861987) were used as
internal controls on each plate for Gram-negative and Gram-
positive bacteria, respectively.
Antifungal assays
For the fungal assays, both fungi (yeast) strains were cultured
for 3 days on Yeast Extract-Peptone Dextrose (YPD; Becton
Dickinson 242720) agar at 30 C. A yeast suspension of 1  106
to 5  106 CFU mL1 (as determined by OD530) was prepared
from ve colonies from the agar plates, and subsequently
diluted with Yeast Nitrogen Base media (YNB; Becton Dickinson
233520), and added to each well of the compound-containing
plates (384-well plates, NBS; Corning CLS3640) giving a nal cell
density of 2.5  103 CFU mL1 and a total volume of 50 mL.
Plates were covered and incubated at 35 C for 36 h without
shaking. Growth inhibition of C. albicans was determined by
measuring absorbance at 630 nm (OD630), while the growth
inhibition of C. neoformans was determined by measuring the
difference in absorbance between 600 and 570 nm (OD600–570),
aer the addition of resazurin (0.001% nal concentration;
Sigma R7017) and incubation at 35 C for 2 h, using media-only
as negative control and fungi without inhibitors as positive
control. MIC values were determined as the lowest concentra-
tion at which the growth was inhibited at $80%. Fluconazole
(Sigma F8929) was used as internal control on each plate for
both strains.
Cytotoxicity assays
HEK293 ATCC CRL-1573 human embryonic kidney cells were
counted manually in a Neubauer haemocytometer and added to
compound-containing plates (384-well plates, tissue culture
treated (TC); Corning CLS3712) giving a nal density of 5000
cells per well in a and a total volume of 50 mL, using Dulbecco's2636 | Chem. Sci., 2020, 11, 2627–2639Modied Eagle Medium (DMEM; Life Technologies 11995-073)
with 10% Foetal Bovine Serum (FBS; GE SH30084.03). The cells
were incubated together with the compounds for 20 h at 37 C
in 5% CO2. Cytotoxicity (or cell viability) was measured by
uorescence, ex: 560/10 nm, em: 590/10 nm (F560/590), aer
addition of 5 mL of 25 mg mL1 resazurin (2.3 mg mL1 nal
concentration; Sigma R7017) and aer further incubation for
3 h at 37 C in 5%CO2, usingmedia-only as negative control and
cells without inhibitors as positive control. CC50 (concentration
at 50% cytotoxicity) were calculated by curve-tting the inhibi-
tion values vs. log(concentration) using a sigmoidal dose–
response function, with variable tting values for bottom, top
and slope. Tamoxifen (Sigma T5648) was used as internal
control on each plate.Haemolysis assays
Human whole blood (Australian Red Cross) was washed three
times with 3 volumes of 0.9% NaCl and resuspended in
a concentration of 0.5  108 cells per mL, determined by
manual cell count in a Neubauer haemocytometer. Washed
cells were added to compound containing plates (384-well
polypropylene plates (PP); Corning 3657) for a nal volume of 50
mL, shaken and incubated for 1 h at 37 C. Aer incubation, the
plates were centrifuged at 1000 g for 10 min to pellet cells and
debris, 25 mL of the supernatant was then transferred to reading
plates (384 well, polystyrene plated (PS), Corning CLS3680), with
haemolysis determined by measuring the supernatant absor-
bance at 405 mm (OD405), using cells without inhibitors as
negative control and cells with 1% Triton X-100 (Sigma T8787)
as positive control. HC10 and HC50 (concentration at 10% and
50% haemolysis, respectively) were calculated by curve tting
the inhibition values vs. log(concentration) using a sigmoidal
dose–response function with variable tting values for top,
bottom and slope. Melittin (Sigma M2272) was used as internal
control on each plate.Author contributions
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